Sarilumab side effects

Sarilumab (Sarilumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Salirumab is indicated for the treatment of adult patients with polymyalgia rheumatica who have an inadequate response to corticosteroids or who are intolerant of corticosteroid tapering. Avoid use of salivolumab with biologic DMARDs due to possible increased risk of immunosuppression and infection. It should not be used in patients with active severe infections.

The most common adverse reactions observed with salivolumab in clinical studies (occurring in at least 3% of rheumatoid arthritis patients who received salivolumab in combination with DMARDs) were neutropenia, ALT elevation, injection site erythema, upper respiratory tract infection, and urinary tract infection. Common adverse reactions occurring in ≥5% of patients with polymyalgia rheumatica receiving rilumab were neutropenia (15.3%), leukopenia (6.8%), constipation (6.8%), pruritus rash (5.1%), myalgia (6.8%), fatigue (5.1%), and injection site pruritus (5.1%).

The patent drug of Salirutumab is a new type of drug for treating diseases. It is not yet on the market in China, and therefore it is not covered by medical insurance. Salirumab The common dosage form of the original drug is injection, which has been marketed overseas. The European version of specifications200mg*2 bottles is priced around 17,500 per box (The price may fluctuate due to exchange rates). There are currently no generics of Salirumab produced in other countries.